LOS ANGELES (Reuters) - Amgen Inc (NasdaqGS:AMGN - News), whose cash balance has soared even as its core anemia drug franchise erodes, will outline its strategy -- and likely announce its first dividend -- at a meeting on Thursday with Wall Street.
LOS ANGELES (Reuters) - Amgen Inc (NasdaqGS:AMGN - News), whose cash balance has soared even as its core anemia drug franchise erodes, will outline its strategy -- and likely announce its first dividend -- at a meeting on Thursday with Wall Street.
